PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review
Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSM...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2019-10, Vol.20 (19), p.4886 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 19 |
| container_start_page | 4886 |
| container_title | International journal of molecular sciences |
| container_volume | 20 |
| creator | Van de Wiele, Christophe Sathekge, Mike de Spiegeleer, Bart de Jonghe, Pieter Jan Beels, Laurence Maes, Alex |
| description | Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostate carcinomas, are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient management in several patients. However, the results published thus far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes. |
| doi_str_mv | 10.3390/ijms20194886 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6801742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548601607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-47c9bfa2093d113dc5e4496556be26675f4db1757399a1b5e498a9901caf6153</originalsourceid><addsrcrecordid>eNpdkc1v1DAQxS0EoqVw44wsceFAwN-JOSCtVi1UKnTF5m45jpP1KrFb22nV_76uWqqF04w0Pz3New-A9xh9oVSir24_J4KwZE0jXoBjzAipEBL1y4P9CLxJaY8QoYTL1-CIYt5gQZtjcLvZ_lpVrY6jzc6PcBOSyzF4eDq7lFxZVqP1OcEhRHg-6_EB2obJ9bBd5hATvMw7G2G70x7-Dr7axJCyzhaudTTOh1l_gyu4vUvZzjo7A__YG2dv34JXg56Sffc0T0B7dtquf1YXlz_O16uLyjBMcsVqI7tBEyRpjzHtDbeMScG56CwRouYD6ztc85pKqXFXrrLRUiJs9CAwpyfg-6Ps1dLNtjfFStSTuopu1vFOBe3UvxfvdmoMN0o0CNeMFIFPTwIxXC82ZVVyMXaatLdhSYpQhBltKKYF_fgfug9L9MWdIpw1AmGB6kJ9fqRMCSpFOzw_g5F6KFQdFlrwD4cGnuG_DdJ79xWcdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548601607</pqid></control><display><type>article</type><title>PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Van de Wiele, Christophe ; Sathekge, Mike ; de Spiegeleer, Bart ; de Jonghe, Pieter Jan ; Beels, Laurence ; Maes, Alex</creator><creatorcontrib>Van de Wiele, Christophe ; Sathekge, Mike ; de Spiegeleer, Bart ; de Jonghe, Pieter Jan ; Beels, Laurence ; Maes, Alex</creatorcontrib><description>Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostate carcinomas, are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient management in several patients. However, the results published thus far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20194886</identifier><identifier>PMID: 31581638</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Antigens, Surface - metabolism ; Brain tumors ; Clear cell-type renal cell carcinoma ; Diagnosis, Differential ; Diagnostic systems ; Fluorodeoxyglucose F18 ; Glioma ; Glioma cells ; Glutamate Carboxypeptidase II - metabolism ; Hepatocellular carcinoma ; Humans ; Immunohistochemistry ; Kidney cancer ; Liver cancer ; Lymphatic system ; Medical imaging ; Metastasis ; Neoplasms - diagnosis ; Neoplasms - metabolism ; Patients ; Positron emission ; Positron emission tomography ; Positron-Emission Tomography - methods ; Prostate ; Prostate cancer ; Prostate carcinoma ; Radiopharmaceuticals ; Review ; Solid tumors ; Tomography ; Tumors</subject><ispartof>International journal of molecular sciences, 2019-10, Vol.20 (19), p.4886</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-47c9bfa2093d113dc5e4496556be26675f4db1757399a1b5e498a9901caf6153</citedby><cites>FETCH-LOGICAL-c412t-47c9bfa2093d113dc5e4496556be26675f4db1757399a1b5e498a9901caf6153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801742/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801742/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31581638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van de Wiele, Christophe</creatorcontrib><creatorcontrib>Sathekge, Mike</creatorcontrib><creatorcontrib>de Spiegeleer, Bart</creatorcontrib><creatorcontrib>de Jonghe, Pieter Jan</creatorcontrib><creatorcontrib>Beels, Laurence</creatorcontrib><creatorcontrib>Maes, Alex</creatorcontrib><title>PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostate carcinomas, are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient management in several patients. However, the results published thus far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes.</description><subject>Animals</subject><subject>Antigens, Surface - metabolism</subject><subject>Brain tumors</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Diagnosis, Differential</subject><subject>Diagnostic systems</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glioma</subject><subject>Glioma cells</subject><subject>Glutamate Carboxypeptidase II - metabolism</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kidney cancer</subject><subject>Liver cancer</subject><subject>Lymphatic system</subject><subject>Medical imaging</subject><subject>Metastasis</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - metabolism</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Prostate carcinoma</subject><subject>Radiopharmaceuticals</subject><subject>Review</subject><subject>Solid tumors</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1v1DAQxS0EoqVw44wsceFAwN-JOSCtVi1UKnTF5m45jpP1KrFb22nV_76uWqqF04w0Pz3New-A9xh9oVSir24_J4KwZE0jXoBjzAipEBL1y4P9CLxJaY8QoYTL1-CIYt5gQZtjcLvZ_lpVrY6jzc6PcBOSyzF4eDq7lFxZVqP1OcEhRHg-6_EB2obJ9bBd5hATvMw7G2G70x7-Dr7axJCyzhaudTTOh1l_gyu4vUvZzjo7A__YG2dv34JXg56Sffc0T0B7dtquf1YXlz_O16uLyjBMcsVqI7tBEyRpjzHtDbeMScG56CwRouYD6ztc85pKqXFXrrLRUiJs9CAwpyfg-6Ps1dLNtjfFStSTuopu1vFOBe3UvxfvdmoMN0o0CNeMFIFPTwIxXC82ZVVyMXaatLdhSYpQhBltKKYF_fgfug9L9MWdIpw1AmGB6kJ9fqRMCSpFOzw_g5F6KFQdFlrwD4cGnuG_DdJ79xWcdQ</recordid><startdate>20191002</startdate><enddate>20191002</enddate><creator>Van de Wiele, Christophe</creator><creator>Sathekge, Mike</creator><creator>de Spiegeleer, Bart</creator><creator>de Jonghe, Pieter Jan</creator><creator>Beels, Laurence</creator><creator>Maes, Alex</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191002</creationdate><title>PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review</title><author>Van de Wiele, Christophe ; Sathekge, Mike ; de Spiegeleer, Bart ; de Jonghe, Pieter Jan ; Beels, Laurence ; Maes, Alex</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-47c9bfa2093d113dc5e4496556be26675f4db1757399a1b5e498a9901caf6153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antigens, Surface - metabolism</topic><topic>Brain tumors</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Diagnosis, Differential</topic><topic>Diagnostic systems</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glioma</topic><topic>Glioma cells</topic><topic>Glutamate Carboxypeptidase II - metabolism</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kidney cancer</topic><topic>Liver cancer</topic><topic>Lymphatic system</topic><topic>Medical imaging</topic><topic>Metastasis</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - metabolism</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Prostate carcinoma</topic><topic>Radiopharmaceuticals</topic><topic>Review</topic><topic>Solid tumors</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van de Wiele, Christophe</creatorcontrib><creatorcontrib>Sathekge, Mike</creatorcontrib><creatorcontrib>de Spiegeleer, Bart</creatorcontrib><creatorcontrib>de Jonghe, Pieter Jan</creatorcontrib><creatorcontrib>Beels, Laurence</creatorcontrib><creatorcontrib>Maes, Alex</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van de Wiele, Christophe</au><au>Sathekge, Mike</au><au>de Spiegeleer, Bart</au><au>de Jonghe, Pieter Jan</au><au>Beels, Laurence</au><au>Maes, Alex</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-10-02</date><risdate>2019</risdate><volume>20</volume><issue>19</issue><spage>4886</spage><pages>4886-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostate carcinomas, are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient management in several patients. However, the results published thus far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31581638</pmid><doi>10.3390/ijms20194886</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2019-10, Vol.20 (19), p.4886 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6801742 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Antigens, Surface - metabolism Brain tumors Clear cell-type renal cell carcinoma Diagnosis, Differential Diagnostic systems Fluorodeoxyglucose F18 Glioma Glioma cells Glutamate Carboxypeptidase II - metabolism Hepatocellular carcinoma Humans Immunohistochemistry Kidney cancer Liver cancer Lymphatic system Medical imaging Metastasis Neoplasms - diagnosis Neoplasms - metabolism Patients Positron emission Positron emission tomography Positron-Emission Tomography - methods Prostate Prostate cancer Prostate carcinoma Radiopharmaceuticals Review Solid tumors Tomography Tumors |
| title | PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T13%3A58%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PSMA-Targeting%20Positron%20Emission%20Agents%20for%20Imaging%20Solid%20Tumors%20Other%20Than%20Non-Prostate%20Carcinoma:%20A%20Systematic%20Review&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Van%20de%20Wiele,%20Christophe&rft.date=2019-10-02&rft.volume=20&rft.issue=19&rft.spage=4886&rft.pages=4886-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20194886&rft_dat=%3Cproquest_pubme%3E2548601607%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548601607&rft_id=info:pmid/31581638&rfr_iscdi=true |